<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:department>Research and Commercial Division</gtr:department><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9C10D78F-6430-4CA7-9528-B96B0762A4C6"><gtr:id>9C10D78F-6430-4CA7-9528-B96B0762A4C6</gtr:id><gtr:name>Cardiff University</gtr:name><gtr:address><gtr:line1>Research &amp; Consultancy</gtr:line1><gtr:line2>PO Box 923</gtr:line2><gtr:line4>Cardiff</gtr:line4><gtr:line5>South Glamorgan</gtr:line5><gtr:postCode>CF10 3TE</gtr:postCode><gtr:region>Wales</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/95524E5B-E175-4691-AADA-C3E30E53A1F7"><gtr:id>95524E5B-E175-4691-AADA-C3E30E53A1F7</gtr:id><gtr:name>University of Cologne</gtr:name><gtr:address><gtr:line1>Fachbereich Wirtschaft</gtr:line1><gtr:line2>Claudrusstra?e 1</gtr:line2><gtr:line4>D-50678 Cologne</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5E2B04DD-4A03-45ED-9892-61C5CCB8AC68"><gtr:id>5E2B04DD-4A03-45ED-9892-61C5CCB8AC68</gtr:id><gtr:name>Newcastle University</gtr:name><gtr:address><gtr:line1>1 Park Terrace</gtr:line1><gtr:line4>Newcastle Upon Tyne</gtr:line4><gtr:line5>Tyne and Wear</gtr:line5><gtr:postCode>NE1 7RU</gtr:postCode><gtr:region>North East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F9BA76DD-D8D4-4C19-93AF-F65FF3DDDB23"><gtr:id>F9BA76DD-D8D4-4C19-93AF-F65FF3DDDB23</gtr:id><gtr:firstName>Marcela</gtr:firstName><gtr:surname>Votruba</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700949"><gtr:id>D627552C-6748-4E54-97A2-15FB6E3848F9</gtr:id><gtr:title>Mitochondrial shaping proteins in models of optic neuropathy</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700949</gtr:grantReference><gtr:abstractText>Inherited optic neuropathies are amongst the most common causes of childhood blindness in the developed world. Not only are inherited optic neuropathies common but they are also currently completely untreatable and incurable. The purpose of this work is to cast light on strategies for preventing optic neuropathy based on understanding the expression, regulation and modulation of mitochondrial fusion/ fission pathways and mitochondrial shaping genes. There are an increasing number of genes known to be involved in controlling the shape, and hence the function of, mitochondria in the cell. Some have all ready been identified as being involved in causing inherited optic neuropathy. In the short term, new genes need to be discovered to permit diagnostic screening, clinical and molecular diagnosis and management, assessment of genotype/ phenotype correlation and prognostic counselling, and hence improve the global management of these conditions for today?s patients. Concrete outcomes of this research will be to broaden the genetic spectrum of inherited optic neuropathy and cast light on the expression and function of such genes in neural tissue. The research will also focus on developing real animal models of disease by reducing or removing the expression of selected of these genes in the retina and studying the effect this has on mitochondrial shaping and retinal and optic nerve histology and morphology. This will enable an understanding of what role these genes have specifically in causing blindness by their putative effects on retinal ganglion cells. Only by broadening our understanding of this group of physiological vital genes will we be able to understand why abnormalities in this delicate mechanism may lead specifically to blindness.</gtr:abstractText><gtr:technicalSummary>Mitochondrial shaping proteins are fundamental to the control of normal cellular physiolgy, especially in neural tissue, and those identified to date play a significant role in the pathophysiology of human inherited optic neuropathy. However, there is evidence from both genetic studies and basic cell biology for as yet unidentified proteins acting on the mitochondrial inner/ outer membrane in health and disease. The relative expression levels of mitochiondrial pro fusion/ fission genes may dictate mitochondrial morphology in cellular differentiation and during development and may thus play a role in the pathophysiology of disease. This will be explored by addressing the following specific research aims and questions:
Aim 1: identify evidence for new fusion/ fission genes and explore if any are involved in inherited optic neuropathy.
Aim 2: explore the spatio-temporal expression profile for mitochondrial shaping genes and proteins in the normal developing and adult mammalian eye.
Aim 3: generate murine models utilising in vivo knockdown in the eye.
Aim 4: and comprehensively characterise these mutant effects and interactions.

New mitochondrial shaping genes will be identified by homology from other species, or from research on mitochondrial membrane dynamics, and explored as candidate genes for human disease. Candidate gene screening for mutations in a population of patients DNA with inherited or sporadic optic atrophy, in whom mutations in the previously identified genes, OPA1 and OPA3 have been excluded, will be carried out. A novel gene mapped to a novel locus by the Applicant ( OPA7 ) will be identified and screened in the same samples. In order to explore the spatio-temporal expression profile for these genes and proteins in the normal developing and adult mammalian eye the plan is to use RT-PCR, in situ hybridization, immunohistochemistry and western blotting for candidates, including the novel gene discovered by the Applicant. Tissue localisation in adult mouse and human retinal sections, optic nerve and brain will be studied by immunohistochemistry and the overall expression of the gene, and its isoforms, in different tissues will be assessed by RT-PCR using tissue-specific cDNA. Lastly, in vivo modelling in the eye will be achieved utilising knowdown with siRNA in order to study mitochondrial shaping proteins and their pathophysiology. Once this has been achieved there will be a comprehensive characterisation of the mutant line(s) in order to permit the in vivo phenotypic assessment of the pathophysiology of this protein and hence gain invaluable insights into normal function.</gtr:technicalSummary><gtr:fund><gtr:end>2011-10-06</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-07-07</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>399104</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Newcastle University</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Mitochondrial Research Group</gtr:department><gtr:description>NCL PYWM</gtr:description><gtr:id>CB3218AF-BE78-4AC8-AFE9-509E502107DA</gtr:id><gtr:impact>Two publications submitted.
? Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, Toscano A, Musumeci O, Valentino ML, Caporali L, Lamperti C, Tallaksen CM, Duffey P, Miller J, Whittaker RG, Baker MR, Jackson MJ, Clarke MP, Dhillon B, Czermin B, Stewart JD, Hudson G, Reynier P, Bonneau D, Marques W Jr, Lenaers G, McFarland R, Taylor RW, Turnbull DM, Votruba M, Zeviani M, Carelli V, Bindoff LA, Horvath R, Amati-Bonneau P, Chinnery PF. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133: 771-786

? Yu-Wai-Man P, Davies VJ, Piechota MJ, Cree LM, Votruba M, Chinnery PF. Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy. Invest Ophthalmol Vis Sci. 2009; 50: 4561-4566</gtr:impact><gtr:outcomeId>E07F751A3E0-1</gtr:outcomeId><gtr:partnerContribution>Screening samples from tissues and embryos from Opa1 mutant mice for mitochondrial DNA deletions and also screening patients and phenotypes</gtr:partnerContribution><gtr:piContribution>Providing Opa1 mutant embryos and tissues as well as DNA, RNA and technical help. Also providing patient data.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cologne</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Cologne Center for Genomics (CCG)</gtr:department><gtr:description>New ADOA gene</gtr:description><gtr:id>9ABA7436-20E6-47BE-86C8-35B70170E1AF</gtr:id><gtr:impact>Published work.</gtr:impact><gtr:outcomeId>TJd1qFWSKrc-1</gtr:outcomeId><gtr:partnerContribution>Identification of a novel genetic locus for dominant optic atrophy and subsequently a novel disease gene</gtr:partnerContribution><gtr:piContribution>I identified the family in whom the linkage analysis was carried out, I performed initial linkage analysis excluding published genetic loci, I screened for candidate genes, we then did a genome wide linkage analysis and identified a new locus. Next generation sequencing has resulting in the very recent identification of a new disease causing gene.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>UK EGG</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B193F2E1-AD0C-43A3-B9FC-EE39D049C007</gtr:id><gtr:impact>Approx. 90 health and allied professional attended meeting on eye genetics organised and delivered by MV.

Excellent feedback,networking and plans to hold seconf meeting.</gtr:impact><gtr:outcomeId>twi2irFwYP4</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit Cardiff</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>B8958250-365A-4F33-A083-72286BF2BF25</gtr:id><gtr:impact>35 pupils attended an activity centered around genetics.

Positive feedback.</gtr:impact><gtr:outcomeId>JdkTGLDjGGT</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Student</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>77921D11-EB0C-4AD5-9A2F-A9BA9087953F</gtr:id><gtr:outcomeId>tVQUnqnzNHS0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>95000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Fight for Sight PhD Studentship</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>6902DD97-9771-4FE7-9192-51A5BC2BAC81</gtr:id><gtr:outcomeId>AzXYX4hSXH4</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Small Grants Award</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Fight for Sight</gtr:fundingOrg><gtr:id>DDB96F83-F4E2-42B4-811F-B727B1657637</gtr:id><gtr:outcomeId>M5cgK5uv6pM</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>National Eye Research Centre Project Grant</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Eye Research Centre</gtr:fundingOrg><gtr:id>D98B7864-76ED-4A6C-8A7E-BAA510AF8D0E</gtr:id><gtr:outcomeId>RrE6LC8r6wc</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD Student</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Cardiff University</gtr:fundingOrg><gtr:id>815DAFB6-5E97-44EA-AD13-F5DE0D53CDC5</gtr:id><gtr:outcomeId>tVQUnqnzNHS1</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>UK EGG</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>60989A2D-A1CE-4FA3-A59A-854BEAEC6665</gtr:id><gtr:outcomeId>T2iq9xkuYoT</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>OPA1 gene test</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>Testing for inherited optic neuropathy</gtr:guidelineTitle><gtr:id>2A8C1EC9-D9F1-4D8A-BD1F-F5E2E1B892E1</gtr:id><gtr:impact>Improved service delivery of genetic testing for inherited optic neurpathy</gtr:impact><gtr:outcomeId>rbfCE1FP9JW</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Mouse model with new Opa1 mutation leading to Opa1 mislocalization and embryonic lethality when homozygous. heterozygotes bred on to C57Bl/6J line and ocular phenotype analysed.</gtr:description><gtr:id>AF0FD3C5-3729-4465-9531-D8FE39C2FC5A</gtr:id><gtr:impact>Seconf Opa1 mutant line.</gtr:impact><gtr:outcomeId>Cn8UhbJieXk</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Opa1 W616CinsLR</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Novel mutant B6;C3-Opa1 Q285 STOP</gtr:description><gtr:id>2BDC3E4A-DBBF-4C25-A710-F42A7857F947</gtr:id><gtr:impact>ongoing research</gtr:impact><gtr:outcomeId>BB31D5E4D9E</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Opa1 mutant mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>New equipment</gtr:description><gtr:id>4CF6E4AD-5465-40CC-B00A-07727A06B7AA</gtr:id><gtr:impact>Not yet</gtr:impact><gtr:outcomeId>E9D11B2DAE2</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>New -80</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>B6;C3-Opa3 L122P</gtr:description><gtr:id>2635121F-8D95-4AD3-B8FC-8350024306E8</gtr:id><gtr:impact>ongoing reearch</gtr:impact><gtr:outcomeId>1D694108F4B</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Opa3 mutant mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>236C1404-25F3-4CBA-877E-D6863BC22036</gtr:id><gtr:title>Secondary mtDNA defects do not cause optic nerve dysfunction in a mouse model of dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Investigative ophthalmology &amp; visual science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0146-0404</gtr:issn><gtr:outcomeId>93E4EE0027D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>38543883-0039-4D3D-B3A8-0E98042A149A</gtr:id><gtr:title>Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4e2b35510da18c4d24ede0199ba63a6c"><gtr:id>4e2b35510da18c4d24ede0199ba63a6c</gtr:id><gtr:otherNames>Liao C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>58af0320244e12.91823942</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>580E8A83-EA38-4815-A60B-A282477FC8CB</gtr:id><gtr:title>Specific deficits in visual electrophysiology in a mouse model of dominant optic atrophy.</gtr:title><gtr:parentPublicationTitle>Experimental eye research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d129e74703a7266887fd60392d04e001"><gtr:id>d129e74703a7266887fd60392d04e001</gtr:id><gtr:otherNames>Barnard AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-4835</gtr:issn><gtr:outcomeId>TbNaMz748Bd</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D6A69CC0-F77D-4ADC-A432-8BA7F01C8ACF</gtr:id><gtr:title>Mouse models of dominant optic atrophy: what do they tell us about the pathophysiology of visual loss?</gtr:title><gtr:parentPublicationTitle>Vision research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e875ffabc758478aeb78910874f5a6"><gtr:id>27e875ffabc758478aeb78910874f5a6</gtr:id><gtr:otherNames>Williams PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0042-6989</gtr:issn><gtr:outcomeId>AUcjcGkjoLt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>39D2B360-5121-450C-9532-26063F314374</gtr:id><gtr:title>Incidence and patterns of detection and management of childhood-onset hereditary retinal disorders in the UK.</gtr:title><gtr:parentPublicationTitle>The British journal of ophthalmology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f41eca3edc54593f0b102f90d52295ed"><gtr:id>f41eca3edc54593f0b102f90d52295ed</gtr:id><gtr:otherNames>Hamblion EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0007-1161</gtr:issn><gtr:outcomeId>oqA8xjk6etR</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89ED646E-BA40-4B07-9C76-26AC102F69DD</gtr:id><gtr:title>Multi-system neurological disease is common in patients with OPA1 mutations.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5e183f90d0873ec594af1fe0d97529aa"><gtr:id>5e183f90d0873ec594af1fe0d97529aa</gtr:id><gtr:otherNames>Yu-Wai-Man P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>WHt14pYpTcM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>20DAEEAA-89DB-44E6-90D5-41D4FBB0EC44</gtr:id><gtr:title>OPA1 analysis in an international series of probands with bilateral optic atrophy.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fcfbff21c473269b7c1d24798af71ad"><gtr:id>3fcfbff21c473269b7c1d24798af71ad</gtr:id><gtr:otherNames>Liskova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>585d38f4689742.78010297</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55C11857-0B44-41DB-99A8-9A8DA22098A8</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy.</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>pm_13502_22_22966490</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>03FC7E1E-3071-442B-BF7D-5AD50A082936</gtr:id><gtr:title>Retinal ganglion cell dendritic degeneration in a mouse model of Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of aging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e875ffabc758478aeb78910874f5a6"><gtr:id>27e875ffabc758478aeb78910874f5a6</gtr:id><gtr:otherNames>Williams PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0197-4580</gtr:issn><gtr:outcomeId>pm_13502_22_23465714</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A972E3E3-8B6F-4345-8207-DE5259204517</gtr:id><gtr:title>Mitochondrial dysfunction in an Opa1(Q285STOP) mouse model of dominant optic atrophy results from Opa1 haploinsufficiency.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e7e8ce287d20ed07da2785aaf1eba703"><gtr:id>e7e8ce287d20ed07da2785aaf1eba703</gtr:id><gtr:otherNames>Kushnareva Y</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58af02c2960865.60255804</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3B4F205C-12AA-4BB9-821E-8B071B5C6D25</gtr:id><gtr:title>Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion cell dendropathy.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e875ffabc758478aeb78910874f5a6"><gtr:id>27e875ffabc758478aeb78910874f5a6</gtr:id><gtr:otherNames>Williams PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>P2CBKXK5VEe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>40AEDBEB-13EB-4785-9935-557A81E5A383</gtr:id><gtr:title>Opa3, a novel regulator of mitochondrial function, controls thermogenesis and abdominal fat mass in a mouse model for Costeff syndrome.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a37a31beccc4d3e788aefd255bdcc1b0"><gtr:id>a37a31beccc4d3e788aefd255bdcc1b0</gtr:id><gtr:otherNames>Wells T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>pm_13502_22_22869679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A5B0B34-9F4F-4C1B-AFD0-438B76443B8A</gtr:id><gtr:title>A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function.</gtr:title><gtr:parentPublicationTitle>Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e0f9efcf7d9dd79b733acabce34dfa52"><gtr:id>e0f9efcf7d9dd79b733acabce34dfa52</gtr:id><gtr:otherNames>Smith TG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0306-4522</gtr:issn><gtr:outcomeId>56d041c34b22c0.71549639</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>55DD0069-F237-41BF-9FC4-C9EE56C8F989</gtr:id><gtr:title>Novel OPA1 missense mutation in a family with optic atrophy and severe widespread neurological disorder.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3fcfbff21c473269b7c1d24798af71ad"><gtr:id>3fcfbff21c473269b7c1d24798af71ad</gtr:id><gtr:otherNames>Liskova P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>mRoWNfZyJCY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8234F81D-932E-4FF6-92B6-E62FD93F6FBD</gtr:id><gtr:title>Leber's optic neuropathy - visual return on alcohol cessation.</gtr:title><gtr:parentPublicationTitle>Acta ophthalmologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ee5d829b262c712686dc18d707ee62f4"><gtr:id>ee5d829b262c712686dc18d707ee62f4</gtr:id><gtr:otherNames>Morris B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1755-375X</gtr:issn><gtr:outcomeId>pm_13502_22_22405409</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>09D5B18D-0193-4348-BBF8-D454678BB246</gtr:id><gtr:title>Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/27e875ffabc758478aeb78910874f5a6"><gtr:id>27e875ffabc758478aeb78910874f5a6</gtr:id><gtr:otherNames>Williams PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>TBn9gHgs4sQ</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700949</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>A9061818-9B1E-495A-9617-7C77200827C2</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Eye</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>